Cargando…
Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations
Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067356/ https://www.ncbi.nlm.nih.gov/pubmed/36808895 http://dx.doi.org/10.1111/1759-7714.14827 |
_version_ | 1785018446777417728 |
---|---|
author | Sejben, Anita Pancsa, Tamás Tiszlavicz, László Furák, József Paróczai, Dóra Zombori, Tamás |
author_facet | Sejben, Anita Pancsa, Tamás Tiszlavicz, László Furák, József Paróczai, Dóra Zombori, Tamás |
author_sort | Sejben, Anita |
collection | PubMed |
description | Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic, and sarcomatoid MM. Distinction may be a challenging task for the pathologist, due to the unspecific morphology. Here, we present two cases of diffuse MM subtypes to emphasize the immunohistochemical (IHC) differences, and to facilitate diagnostic difficulties. In our first case of epithelioid mesothelioma, the neoplastic cells showed cytokeratin 5/6 (CK5/6), calretinin, and Wilms‐tumor‐1 (WT1) expression, while remaining negative with thyroid transcription factor‐1 (TTF‐1). BRCA1 associated protein‐1 (BAP1) negativity was seen in the neoplastic cells' nucleus, reflecting loss of the tumor suppressor gene. In the second case of biphasic mesothelioma, expression of epithelial membrane antigen (EMA), CKAE1/AE3, and mesothelin was observed, while WT1, BerEP4, CD141, TTF1, p63, CD31, calretinin, and BAP1 expressions were not detected. Due to the absence of specific histological features, the differentiation between MM subtypes could be a challenging task. In routine diagnostic work, IHC may be the proper method in distinction. According to our results and literature data, CK5/6, mesothelin, calretinin, and Ki‐67 should be applied in subclassification. |
format | Online Article Text |
id | pubmed-10067356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-100673562023-04-04 Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations Sejben, Anita Pancsa, Tamás Tiszlavicz, László Furák, József Paróczai, Dóra Zombori, Tamás Thorac Cancer Mini Review Malignant mesothelioma (MM) is a rare tumor of mesothelial cells, with an increasing incidence both in developed and developing countries. MM has three major histological subtypes, in order of frequency, according to the World Health Organization (WHO) Classification of 2021: epithelioid, biphasic, and sarcomatoid MM. Distinction may be a challenging task for the pathologist, due to the unspecific morphology. Here, we present two cases of diffuse MM subtypes to emphasize the immunohistochemical (IHC) differences, and to facilitate diagnostic difficulties. In our first case of epithelioid mesothelioma, the neoplastic cells showed cytokeratin 5/6 (CK5/6), calretinin, and Wilms‐tumor‐1 (WT1) expression, while remaining negative with thyroid transcription factor‐1 (TTF‐1). BRCA1 associated protein‐1 (BAP1) negativity was seen in the neoplastic cells' nucleus, reflecting loss of the tumor suppressor gene. In the second case of biphasic mesothelioma, expression of epithelial membrane antigen (EMA), CKAE1/AE3, and mesothelin was observed, while WT1, BerEP4, CD141, TTF1, p63, CD31, calretinin, and BAP1 expressions were not detected. Due to the absence of specific histological features, the differentiation between MM subtypes could be a challenging task. In routine diagnostic work, IHC may be the proper method in distinction. According to our results and literature data, CK5/6, mesothelin, calretinin, and Ki‐67 should be applied in subclassification. John Wiley & Sons Australia, Ltd 2023-02-20 /pmc/articles/PMC10067356/ /pubmed/36808895 http://dx.doi.org/10.1111/1759-7714.14827 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Mini Review Sejben, Anita Pancsa, Tamás Tiszlavicz, László Furák, József Paróczai, Dóra Zombori, Tamás Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
title | Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
title_full | Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
title_fullStr | Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
title_full_unstemmed | Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
title_short | Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
title_sort | highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations |
topic | Mini Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067356/ https://www.ncbi.nlm.nih.gov/pubmed/36808895 http://dx.doi.org/10.1111/1759-7714.14827 |
work_keys_str_mv | AT sejbenanita highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations AT pancsatamas highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations AT tiszlaviczlaszlo highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations AT furakjozsef highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations AT paroczaidora highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations AT zomboritamas highlightingtheimmunohistochemicaldifferencesofmalignantmesotheliomasubtypesviacasepresentations |